At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
nangibotide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomised, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Ascending, Single, Intravenous Doses of MOTREM (LR12) in Healthy Male Subjects
In Brief
A Phase 1 clinical trial evaluating nangibotide and Placebo for Healthy Subjects. Completed, enrolled 27 participants across 1 site.
Detailed Summary
This was a single center, randomized, placebo-controlled study with a sequential i.v. dose escalation cohorts design, to assess safety, tolerability and pharmacokinetics of MOTREM (nangibotide) in healthy volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Subjects
CountriesUnited Kingdom
CollaboratorsRichmond Pharmacology Limited
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
Primary CompletionAug 2016
First PostedMar 2018
TodayJul 2026
First PostedMar 13, 2018
Enrollment StartApr 1, 2016
Primary CompletionAug 25, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.3 years ago
Interventions
nangibotidedrug
Continous i.v. infusion
Placebodrug
Placebo